Skip to main content
SpringerLink
Log in

The natural course of progressive systemic sclerosis patients with interstitial lung involvement

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objective

The aim of the study is to assess the natural course of systemic sclerosis (SSc) in patients with interstitial lung involvement and to evaluate the effects of treatment.

Materials and methods

Sixty SSc patients with interstitial lung involvement were included in the study and history and retrospective data records of the patients were reviewed.

Results

It was observed that 47 patients (78.3%) had Raynaud’s phenomenon, 7 patients (11.7%) had skin involvement, 5 patients (8.3%) had joint involvement, and 1 patient (1.7%) had gastrointestinal system involvement as the first manifestation of the disease. Lung involvement had developed on an average of 113±106 months after the first manifestation of the disease and was apparent within the first year in 10 patients (16.7%), between 1 and 2 years in 3 patients (5%), between 2 and 3 years in 2 patients (3.3%), between 3 and 4 years in 5 patients (8.3%), between 4 and 10 years in 21 patients (35%), and after 10 years in 19 patients (31.7%). When the symptoms of lung involvement appeared, 37 patients (61.7%) were not receiving treatment while 23 (38.3%) were using an immunosuppressive agent. The time interval of lung involvement for the treated patients was 131±95 months while it was 101±112 months in untreated patients (p>0.05).

Conclusion

In SSc patients with intersititial pulmonary involvement, the disease frequently starts with Raynaud’s phenomenon and pulmonary symptoms tend to appear at a mean of 7 years after the onset of disease. The first sign of the disease, the probability of interstitial pulmonary involvement, is highest during the first 15 years after. Although this probability decreases after 15 years, in up to 10% of the patients, interstitial pulmonary involvement can still occur even up to 40 years. Immunosuppressive treatment is not effective in preventing the development of pulmonary involvement. However, it delays the manifestation of pulmonary symptoms for nearly 4 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Black CM, Stephens SC (1993) Systemic sclerosis (scleroderma) and related disorders. In: Maddison PJ, Isenberg DA, Woo P, Glass DN (eds) Oxford textbook of rheumatology. Oxford University Press, Oxford, pp 771–789

    Google Scholar 

  2. Medsger TA (1993) Systemic sclerosis (scleroderma), localized scleroderma, eosinophilic fasciitis and calcinosis. In: McCarty DJ, Koopman WJ (eds) Arthritis and allied conditions, 12th edn. Lea and Febiger, Philadelphia, pp 1113–1143

    Google Scholar 

  3. Seibold JR (1997) Scleroderma. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 1133–1163

    Google Scholar 

  4. Le Roy EC (1996) Systemic sclerosis (scleroderma). In: Bennet SC, Plumm F, Glass DN (eds) Cecil’ s textbook of medicine. Saunders, Philadelphia, pp 1183–1188

    Google Scholar 

  5. Wigley MF (1998) Systemic sclerosis. In: Klippel JK, Dieppe PA (eds) Rheumatology. Mosby, St Louis, pp 79.1–79.14

    Google Scholar 

  6. Veale DJ, Collidge TA, Belch JJ (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54:853–855

    PubMed  CAS  Google Scholar 

  7. Silman A, Jannini S, Symmons D et al (1988) An epidemiologic study of scleroderma in West Midlands. Br J Rheumatol 27(4):286–290

    Article  PubMed  CAS  Google Scholar 

  8. Geirsson AJ, Steinsson K, Guthmundsson S et al (1994) Systemic sclerosis in Iceland. A nationwide epidemiologic study. Ann Rheum Dis 53(8):502–505

    PubMed  CAS  Google Scholar 

  9. Roberts-Thomson PJ, Jones M, Hakendorf P et al (2001) Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J 31(4):220–229

    Article  PubMed  CAS  Google Scholar 

  10. Steen VD, Oddis CV, Conte CG et al (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum 40(3):441–445

    PubMed  CAS  Google Scholar 

  11. Mayes M, Laing T, Gillespie B et al (1996) Prevalence, incidence and survival rates of systemic sclerosis in the Detroit Metropolitan Area. Arthritis Rheum 39:S150, (Suppl)

    Google Scholar 

  12. Rossa AD, Valentini G, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 60:585–591

    Article  PubMed  Google Scholar 

  13. Coghlan JG, Mukerjee D (2001) The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol 13(6):495–499

    Article  PubMed  CAS  Google Scholar 

  14. Garber SJ, Wells AU, duBois RM et al (1992) Enlarged mediastinal lymph nodes in the fibrosing alveolitis of systemic sclerosis. Br J Radiol 65(779):983–986

    PubMed  CAS  Google Scholar 

  15. Schurawitzki H, Stiglbauer R, Granibger W et al (1990) Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 176(3):755–759

    PubMed  CAS  Google Scholar 

  16. Griedinger EL, Flaherty KT, White B et al (1998) African American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 114:801–807

    Google Scholar 

  17. Steen VD, Conte C, Owens GR et al (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283–1289

    Google Scholar 

  18. Steen VD, Medsger JR TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43 (11):2437–2444

    Article  PubMed  CAS  Google Scholar 

  19. Shuford WH, Seaman WB, Goldman A (1953) Pulmonary manifestations of scleroderma. Arch Intern Med 92:85–97

    CAS  Google Scholar 

  20. Weaver AL, Divertie MB, Titus JL (1987) The lung in scleroderma. Mayo Clin Proc 42:754–766

    Google Scholar 

  21. Spain DM, Thomas AG (1950) The pulmonary manifestations of scleroderma: an anatomic–physiologic correlation. Ann Intern Med 32:152–161

    PubMed  CAS  Google Scholar 

  22. Rodnan GP (1963) The natural history of progressive systemic sclerosis (diffuse scleroderma). Bull Rheum Dis 13:301–304

    PubMed  CAS  Google Scholar 

  23. Antony TH, Lin MD, Philip J et al (2003) Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am 29:409–426

    Article  Google Scholar 

  24. White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 29:371–390

    Article  PubMed  Google Scholar 

  25. Subcomittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(3):581–586

    Google Scholar 

  26. Bluestone R, Grahame R, Holloway V et al (1970) Treatment of systemic sclerosis with d-penisillamine. A new method of observing the effects of treatment. Ann Rheum Dis 29:153–158

    PubMed  CAS  Google Scholar 

  27. Steen VD, Medsger TA, Rodnan GP (1982) d-Penisillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 97:652–659

    PubMed  CAS  Google Scholar 

  28. Jimenez SA, Sigal SH (1991) A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with d-penisillamine. J Rheumatol 18:1496–1503

    PubMed  CAS  Google Scholar 

  29. Kang B, Veres-Thorner C, Heredia R et al (1982) Successful treatment of far-advanced progressive systemic sclerosis by d-penicillamine. J Allergy Clin Immunol 69:279–305

    Article  Google Scholar 

  30. Steen VD, Owens GR, Redmond C et al (1985) The effect of d-penisillamine on pulmonary findings in progressive systemic sclerosis. Arthritis Rheum 28:882–888

    PubMed  CAS  Google Scholar 

  31. DeClerck LS, Dequeker J, Francx L, Demedts M (1987) d-Penicillamine therapy and interstitial lung disease in scleroderma. Arthritis Rheum 30(6):643–650

    CAS  Google Scholar 

  32. Thomson J, Milne JA (1974) Two years of penicillamine for progressive syclerosis: a case report. Postgrad Med J 5:36–38

    Google Scholar 

  33. Smiley JD, Johnson RL Jr, Ziff M (1967) Effect of d-penicillamine on pulmonary function in patients with progressive systemic sclerosis (abstract). Arthritis Rheum 10:313–314

    Google Scholar 

  34. Clements PJ, Furst DE, Wong WK et al (1999) High-dose versus low-dose d-penisillamine in early diffuse systemic sclerosis analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194–1203

    Article  PubMed  CAS  Google Scholar 

  35. Rodnan GP, Black RL, Bollet AJ, Býnim JJ (1956) Observations on the use of prednisone in patients with progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 44:16–29

    PubMed  CAS  Google Scholar 

  36. Van den Hoogen FH, Boerbooms AM, Van de Putte LB et al (1989) Methotrexate treatment in scleroderma. Am J Med 87:116–117

    PubMed  Google Scholar 

  37. Van den Hoogen FH, Boerbooms AM, Van de Putte LB et al (1991) Low dose methotrexate treatment in systemic sclerosis [letter]. J Rheumatol 18:1763–1764

    PubMed  Google Scholar 

  38. Van den Hoogen FH, Boerbooms AM, Swaak AJ et al (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35:364–372

    Article  PubMed  Google Scholar 

  39. Pope JE, Bellamy N, Seibold JR et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351–1358

    Article  PubMed  CAS  Google Scholar 

  40. Silver RM, Warrick JH, Kinsella MB et al (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844

    PubMed  CAS  Google Scholar 

  41. Akesson A, Scheja A, Lundin A et al (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729–735

    PubMed  CAS  Google Scholar 

  42. Steen VD, Lanz KJ, Conte C et al (1994) Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37:1290–1296

    PubMed  CAS  Google Scholar 

  43. Davas E, Peppas C, Maragou M et al (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:458–461

    Google Scholar 

  44. Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) Randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25(2):205–212

    Article  PubMed  CAS  Google Scholar 

  45. White B, Moore WC, Wigley FM et al (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947–954

    PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Ikitimur Hande

    Present address: Adnan Kahveci Bulvarý Rontgen sokak, No. 34/23 Bahcelievler, 34180, Istanbul, Turkey

Authors and Affiliations

  1. Department of Pulmonary Diseases, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

    Musellim Benan, Ikitimur Hande & Ongen Gul

Authors
  1. Musellim Benan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ikitimur Hande
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ongen Gul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ikitimur Hande.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benan, M., Hande, I. & Gul, O. The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol 26, 349–354 (2007). https://doi.org/10.1007/s10067-006-0302-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0302-6

Keywords

Search

Navigation